2011

Hanova M, Vodickova L, Vaclavikova R, Smerhovsky Z, Stetina R, Hlavac P, Naccarati A, Slyskova J, Polakova V, Soucek P, Kumar R, Hemminki K, Vodicka P. DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (TP53, p21CDKN1A, BCL2 and BAX) with respect to occupational exposure to styrene. Carcinogenesis 2011;32(1):74-9. IF₂₀₀₉ = 4.80

Mohelnikova-Duchonova B, Marsakova L, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Slamova A, Schejbalova M, Soucek P. Superoxide Dismutase and NAD(P)H Quinone Oxidoreductase Polymorphisms and Pancreatic Cancer Risk. Pancreas 2011;40(1):72-78. IF₂₀₀₉ = 2.73

Soucek P, Kondrova E, Hermanek J, Stopka P, Boumendjel A, Ueng YF, Gut I. New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anticancer Drugs. 2011;22(2):176-84. IF₂₀₀₉ = 2.23

Hughes D, Hlavatá I, Soucek P, Pardini B, Naccarati A, Vodickova L, O'Morain C, Vodicka P. Ornithine Decarboxylase G316A Genotype and Colorectal Cancer Risk. Colorectal Dis 2011;13(8):860-4. IF₂₀₀₉ = 2.41

Hughes DJ, Hlavatá I, Soucek P, Pardini B, Naccarati A, Vodickova L, Jenab M, O’Morain C, and Vodicka P. Variation in the Vitamin D receptor gene is not associated with Colorectal Cancer in the Czech Republic. Journal of Gastrointestinal Cancer 2011;42(3):149-54.

Ueng YF, Chen CC, Chung YT, Liu TY, Chang YP, Lo WS, Murayama N, Yamazaki H, Souček P, Chau GY, Chi CW, Chen RM, Li DT. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol. 2011;163(6):1250-62. IF₂₀₀₉ = 5.20

Havranek O, Spacek M, Hubacek P, Mocikova H, Benesova K, Soucek P, Trneny M, Kleibl Z. No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma. Leukemia Lymphoma. 2011;35(8):1117-9. IF₂₀₀₉ = 2.397

Otová B, Ojima I, Václavíková R, Hrdý J, Ehrlichová M, Souček P, Vobořilová J, Němcová V, Zanardi I, Horský S, Kovář J, Gut I. Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Invest New Drugs. 2011 Mar 30. [Epub ahead of print] IF₂₀₀₉ = 3.07

Hubackova M, Vaclavikova R, Ehrlichova M, Mrhalova, Kodet R, Kubackova K, Vrána D, Gut I, Soucek P. Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer. 2011, Feb 23. doi: 10.1002/ijc.26006. [Epub ahead of print]. IF₂₀₀₉ = 4.72

2010

Vrana D, Novotny J, Holcatova I, Hlavata I, Soucek P. CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival. Neoplasma 2010;57(1):15-9. IF₂₀₀₉ = 1.19

Mohelnikova-Duchonova B, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Soucek P. CYP2A13, ADH1B and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk. Pancreas 2010;39(2):144-148. IF₂₀₀₉ = 2.73

Chou YC, Chung YT, Liu TY, Wang SY, Chau GY, Chi CW, Soucek P, Krausz KW, Gelboin HV, Lee CH, Ueng YF. The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J Pharmacol Sci 2010;99(2):1063-77. IF₂₀₀₉ = 2.18

Naccarati A, Pardini B, Polakova V, Smerhovsky Z, Vodickova L, Soucek P, Vrana D, Holcatova I, Ryska M, Vodicka P. Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. Carcinogenesis 2010;31(4):666-70. IF₂₀₀₉ = 4.80

Mateju M, Stribrna J, Zikan M, Kleibl Z, Janatova M, Kormunda S, Novotny J, Soucek P, Petruzelka L, Pohlreich P. Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers. Neoplasma 2010;57(3):280-5. IF₂₀₀₉ = 1.19

Méplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, Hlavatá I, Vrána D, Vodicka P, Hesketh JE. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010;31(6):1074-9. IF₂₀₀₉ = 4.80

Soucek P, Susova S, Mohelnikova-Duchonova B, Gromadzinska J, Morawiec-Sztandera A, Vodicka P, Vodickova L. Polymorphisms in xenobiotic-metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. Neoplasma 2010;57(5):415-21. IF₂₀₀₉ = 1.19

Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati B, Vodicka P, Novotny J, Mohelnikova-Duchonova B, Soucek P. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1, and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep. 2010;24(5):1347-53. IF₂₀₀₉ = 1.59

Mohelnikova-Duchonova B, Havranek O, Hlavata I, Foretova L, Kleibl Z, Pohlreich P, Soucek P. CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer. Cancer Epidemiology 2010;34(5):656-658. IF₂₀₀₉ = 2.06

Hanova M, Stetina R, Vodickova L, Vaclavikova R, Hlavac P, Smerhovsky Z, Naccarati A, Polakova V, Soucek P, Kuricova M, Manini P, Kumar R, Hemminki K, Vodicka P. Modulation of DNA repair capacity and mRNA expression levels of XRCC1, hOGG1 and XPC genes in styrene-exposed workers. Toxicol Appl Pharmacol 2010;248(3):194-200. IF₂₀₀₉ = 3.36

Mohelníková-Duchoňová B, Souček P. Role membránových transportérů v chemorezistenci karcinomu pankreatu při terapii gemcitabinem. Klin Onkol. 2010;23(5):306-10. Review, in Czech.

Souček P: Význam genetických polymorfismů enzymů metabolizujících léčiva u nádorových onemocnění. In: Metabolismus léčiv a jiných xenobiotik (Ed. Skálová L. a kolektiv), vydalo Karolinum v Praze 2010, s.116-122, Monography in Czech.

2009

Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, Soucek P. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer, 2009;45(4):618-24. IF = 4.12

Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I and Soucek P. NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not co-segregate with clinico-pathological characteristcs of human mammary tumors. Pharmacogenet Genomics 2009;19(7):505-512. IF = 3.99

Pardini B, Naccarati A, Polakova V, Smerhovsky Z, Hlavata I, Soucek P, Novotny J, Vodickova L, Tomanova V, Landi S, Vodicka P. NBN 657del(5) heterozygous mutations and colorectal cancer risk in the Czech Republic. Mutat Res- Fund Mol M 2009;666(1-2):64-7. IF = 3.56

Ueng YF, Chen CC, Tsai CC, Soucek P. Differential inductive profiles of hepatic cytochrome P450s by the extracts of Sophora flavescens in male and female C57BL/6JNarl mice. J Ethnopharmacol 2009;10;126(3):437-46. IF = 2.32

Vodicka P, Naccarati A, Vodickova L, Polakova V, Dusinska M, Musak L, Halasova E, Susova S, Soucek P, Hemminki K. Do GST polymorphisms modulate the frequency of chromosomal aberrations in healthy subjects? Environ Health Perspect 2009;117(9):A384-5. IF = 6.19

Vrana D, Pikhart H, Mohelnikova-Duchonova B, Holcatova I, Strnad R, Slamova A, Schejbalova M, Ryska M, Susova S, Soucek P. The association between Glutathione S-transferase Gene polymorphisms and pancreatic cancer in Central European Slavonic population. Mutat Res-Gen Tox Environm Mutag 2009;680:78–81. IF = 2.55

Holcátová I, Souček P, Vrána D, Slámová A, Schejbalová M, Ryska M, Brabec M. Nádory slinivky břišní II. Potenciální rizikové faktory. Praktický lékař 2009;8: 462.